A multi-centre long term follow-up study to assess the durability of sustained virologic response in alisporivir treated chronic hepatitis C patients
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Alisporivir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.
- 10 Jun 2017 Biomarkers information updated
- 30 May 2015 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
- 18 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.